Home » Topics » BioWorld Science, Immune

BioWorld Science, Immune
RSS

Gardasil 9 approved by FDA for adults aged 27-45 years

Oct. 8, 2018

Truly Translational Sweden identifies new sulfasalazine prodrugs

Oct. 3, 2018

NO signals quorum for macrophages

Oct. 1, 2018

MJ8VAX vaccine demonstrates safety and immunogenicity in healthy adults

Sep. 28, 2018

FDA approves pediatric dose of Symjepi for emergency treatment of allergic reactions

Sep. 28, 2018

Positive final topline data presented from two phase II studies of imlifidase

Sep. 28, 2018

Novavax opens phase II trial of NanoFlu

Sep. 27, 2018

Medshine Discovery divulges S1P1 receptor agonists

Sep. 26, 2018

Polymorphisms in donor CYP3A5 and ABCB1 do not impact clinical outcome after kidney transplantation

Sep. 26, 2018

Mesoblast reports survival outcomes through day 180 in phase III study of remestemcel-L

Sep. 21, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...